OptimizeRx Corp OPRX
Business Services · data as of November 13, 2026
OptimizeRx Corp (OPRX) is a consumer discretionary company listed in the US with a market value of about $138M. In the twelve months to September 30, 2026 it had revenue of $94M and net income of $5M, a net margin of 5.3%.
Its overall Stock Analiz score is 2.0 out of 5 (weak). The strongest part is future growth (4/5); the weakest is shareholder returns (0/5).
Key numbers: a P/E of 29.4, a price to free cash flow of 7.0, 5-year revenue growth of 20% a year, a 5-year average ROIC of -4%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 34% below the current price.
About OptimizeRx
OptimizeRx is listed in the US and classified in business services. Revenue went from $7M in 2014 to $109M in 2025, growth of about 29.3% a year. It was profitable in 3 of the last 10 years in our data. Its share count rose by 7% over three years (dilution for shareholders).
Score: 2.0 / 5
Checks passed
- P/FCF below 20
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Positive free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $94M | $109M | $92M | $72M | $62M | $61M | $43M | $25M | $21M | $12M | $8M |
| Net income | $5M | $5M | -$20M | -$18M | -$11M | $378079 | -$2M | -$3M | $226344 | -$2M | -$2M |
| Free cash flow | $20M | $19M | $5M | -$7M | $11M | $625717 | -$6M | -$2M | $758193 | -$2M | -$644399 |
| EPS (diluted) | $0.25 | $0.27 | $-1.10 | $-1.03 | $-0.64 | $0.02 | $-0.15 | $-0.23 | $0.02 | $-0.21 | $-0.05 |
| Net margin | 5.3% | 4.7% | -21.8% | -24.6% | -18.3% | 0.6% | -5.1% | -12.8% | 1.1% | -17.3% | -19.9% |
| ROIC | — | 5.6% | -7.1% | -11.1% | -7.7% | 0.2% | -3.4% | -6.3% | 0.8% | -27.1% | -16.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 5 analysts is $11.90, 62% above the current price; targets range from $10.00 to $18.00; the consensus rating is “Strong buy”; expected EPS is $0.84 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is OptimizeRx’s P/E ratio?
About 29.4, based on the last twelve months of diluted earnings per share (forward P/E about 6.9).
Is OptimizeRx stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 34% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does OptimizeRx pay a dividend?
Not currently.
Is OptimizeRx a good stock to buy?
We do not give buy or sell advice. OptimizeRx scores 2.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.